Clinical trials: Amyotrophic Lateral Sclerosis (ALS)
Amyotrophic Lateral Sclerosis
Growth Hormone in Amyotrophic Lateral Sclerosis
Several drugs have been proposed for ALS. These drugs included: Topiramate, Lamotrigine, creatine, Vit. E, Pentoxifylline, etc. Although most of the trials showed a positive trend, none of them reached a statistically significant…
- Trial name
- NCT00635960
- Testing
- Growth Hormone (Somatropin)
- Where
- 2 sites in Italy
- Volunteers
- 40 people
- Sponsor
- Federico II University
Parkinson Disease, Amyotrophic Lateral Sclerosis
Incobotulinum Toxin A for Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS)
The purpose of this study is to evaluate the safety and efficacy of Incobotulinum Toxin A (Xeomin®) injections into the parotid and submandibular glands in patients with Parkinson's Disease/Parkinsonism and Amyotrophic Lateral…
- Trial name
- Xeomin (NCT01565395)
- Testing
- Incobotulinum Toxin A
- Where
- United States
- Sponsor
- Beth Israel Deaconess Medical Center
Amyotrophic Lateral Sclerosis
Home Care Needs and Current Nursing Status of Patients With Amyotrophic Lateral Sclerosis
The purpose of this study is to comprehensively investigate and analyze the home care needs and status quo of ALS patients in China, and to clarify their home care needs and status quo, so as to provide reference for the…
- Trial name
- NCT04953481
- Testing
- survey
- Where
- China
- Volunteers
- 252 people
- Sponsor
- Peking University Third Hospital
Amyotrophic Lateral Sclerosis (ALS)
A Clinical Trial to Learn About the Effects of VHB937 in People With Amyotrophic Lateral Sclerosis (ALS)
This is a multicenter, randomized, double-blind, placebo-controlled, parallel group Phase II study to evaluate the efficacy and safety of VHB937 in participants with early-stage ALS (within 2 years of ALS symptoms onset).
- Trial name
- ASTRALS (NCT06643481)
- Testing
- VHB937
- Where
- 74 sites in United States, Australia and 15 more
- Volunteers
- 251 people
- Sponsor
- Novartis Pharmaceuticals
Amyotrophic Lateral Sclerosis
Noninvasive Assessment of Neuronal Damage by MRI Sodium ( 23Na ) in Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease affecting the central and peripheral motor neurons, characterized by the rapidity of its evolution (median survival of 3 years).
- Trial name
- NCT02874209
- Testing
- sodium MRI
- Where
- France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Assistance Publique Hopitaux De Marseille
Amyotrophic Lateral Sclerosis
Evaluation the Efficacy and Safety of Mutiple Lenzumestrocel (Neuronata-R® Inj.) Treatment in Patients With ALS
ALSUMMIT is a double-blind, randomized, placebo-controlled, multi-center, parallel, phase III clinical trial to evaluate and confirm the efficacy and long-term safety of repeated Lenzumestrocel (Neuronata-R® inj.) treatment.
- Trial name
- ALSummit (NCT04745299)
- Testing
- Lenzumestrocel, Riluzole
- Where
- 5 sites in South Korea
- Volunteers
- 123 people
- Sponsor
- Corestemchemon, Inc.
Amyotrophic Lateral Sclerosis
Trial of Theracurmin for Patients With Amyotrophic Lateral Sclerosis (ALS)
This will be a 6-month, widely inclusive, virtual, single-center, open-label pilot trial utilizing a historical control group.
- Trial name
- NCT04499963
- Testing
- Theracurmin HP
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Richard Bedlack, M.D., Ph.D.
Amyotrophic Lateral Sclerosis, Health Adult Subjects
Alter-Ego as an Assistive Robotic Device.
The ALTER-EGO study is a monocentric, observational clinical investigation designed to evaluate the safety, usability, and feasibility of the humanoid robotic platform Alter-Ego as an assistive device in hospital and simulated…
- Trial name
- Alter-Ego (NCT07572838)
- Where
- Italy
- Volunteers
- 52 people
- Sponsor
- University of Pisa
Complete or Incomplete Paraplegia/quadriplegia, Spinal Cord Injury
Research on Wireless Brain Implant System for General Control of External Devices
The clinical trial aims to evaluate the safety and efficacy of the minimally invasive, wireless brain-machine interface system (WRS) in enabling general brain control of external devices, such as a cursor and other assistive…
- Conditions
- Complete or Incomplete Paraplegia/quadriplegia, Spinal Cord Injury, Brainstem Stroke, Amyotrophic Lateral Sclerosis
- Trial name
- RISE (NCT06829212)
- Testing
- WRS
- Where
- China
- Volunteers
- 4 people
- Sponsor
- Shanghai StairMed Technology Co., Ltd.
Amyotrophic Lateral Sclerosis
Intraspinal Transplantation of Autologous ADRC in ALS Patients
The goal of our nonrandomized, open label study is to investigate the safety and efficacy of autologous adipose derived mesenchymal regenerative cells (ADRC) transplantation into the individuals with diagnosed amyotrophic lateral…
- Trial name
- ADIPOSTEM (NCT03296501)
- Testing
- Cell-based therapy of autologous adipose derived regenerative cells transplanted intraspinally and intrathecally in ALS patients
- Where
- Poland
- Volunteers
- 30 people
- Sponsor
- Mossakowski Medical Research Centre Polish Academy of Sciences
Amyotrophic Lateral Sclerosis
Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS)
The purpose of the study is to evaluate the effects of the investigational drug, SB-509 on progression of the disease in subjects with ALS
- Trial name
- ALS (NCT00748501)
- Testing
- SB-509
- Where
- 6 sites in United States
- Volunteers
- 45 people
- Sponsor
- Sangamo Therapeutics
ALS (Amyotrophic Lateral Sclerosis), TBI Traumatic Brain Injury
Augmented Reality BCI Longitudinal Study for Persons With ALS, Stroke, TBI and SCI Utilizing Cognixion + Apple Vision Pro
The goal of this study is refine the usability of a BCI capable communication platform. The study will take place in the United States area and will enroll up to 10 participants with late stage ALS, traumatic brain injury (TBI)…
- Conditions
- ALS (Amyotrophic Lateral Sclerosis), TBI Traumatic Brain Injury, SCI - Spinal Cord Injury, Stroke
- Trial name
- NCT07209943
- Testing
- Cognixion + Apple Vision Pro
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Cognixion
Amyotrophic Lateral Sclerosis (ALS)
Effects of L-Carnitine in Amyotrophic Lateral Sclerosis Patients With CHCHD10 Mutations
The study was designed as a single-center, open-label, single-arm pilot study to estimate the safety and efficacy L-carnitine in ALS patients with CHCHD10 mutations.
- Trial name
- NCT06849115
- Testing
- L-Carnitine Injection，1000mg once daily
- Where
- China
- Volunteers
- 4 people
- Sponsor
- ChaodongWang
Amyotrophic Lateral Sclerosis
Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)
This is the study of AMT-162 in Participants with SOD1-ALS and is designed to evaluate the safety, tolerability, and exploratory efficacy of intrathecally administered gene therapy AMT-162.
- Trial name
- NCT06100276
- Testing
- AMT-162
- Where
- 12 sites in United States, Sweden
- Volunteers
- 20 people
- Sponsor
- UniQure Biopharma B.V.
Amyotrophic Lateral Sclerosis
Repetitive Transcranial Magnetic Stimulation as Therapy for Apathy in Amyotrophic Lateral Sclerosis
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive loss of central and peripheral motor neurons. ALS leads to death usually within 3 to 5 years from the onset of the symptoms.
- Trial name
- NCT03892382
- Testing
- rTMS
- Where
- Poland
- Sponsor
- Jagiellonian University
Amyotrophic Lateral Sclerosis
Quality of Life Evaluation with the SRI Questionnaire of ALS Patient with Non-invasive Ventilation
This study aims to measure the quality of life of ALS patients by the SRI questionnaire, in two distinct patient groups : Patient requiring initiation of NIV, and patients 24 hours dependent on NIV This study also seeks to assess…
- Trial name
- Quality EvALS (NCT05498883)
- Testing
- Score completion
- Where
- France
- Volunteers
- 93 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Amyotrophic Lateral Sclerosis
The Effect of RNS60 on ALS Biomarkers
Amyotrophic Lateral Sclerosis (ALS) is a rare lethal neurodegenerative disease involving inflammation. Riluzole, the only drug for ALS, improves median survival by 3 months. This prompts new treatments of ALS.
- Trial name
- RNS60 (NCT03456882)
- Testing
- RNS60
- Where
- 23 sites in United States, Italy
- Volunteers
- 147 people
- Sponsor
- Mario Negri Institute for Pharmacological Research
Amyotrophic Lateral Sclerosis
First Time in Human Study of GSK1223249 in Amyotrophic Lateral Sclerosis
The drug being tested in this study is GSK1223249. It is being developed by GlaxoSmithKline to treat symptoms in patients with Amyotrophic Lateral Sclerosis (ALS).
- Trial name
- NCT00875446
- Testing
- GSK1223249
- Where
- 12 sites in United States, France and 2 more
- Volunteers
- 76 people
- Sponsor
- GlaxoSmithKline
Amyotrophic Lateral Sclerosis
Exogenous Toxicants and Genetic Susceptibility in ALS
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a fatal neurodegenerative disease that poses a significant burden for affected individuals and their family members.
- Trial name
- NCT00011154
- Volunteers
- 525 people, healthy volunteers welcome
- Sponsor
- National Institute of Environmental Health Sciences (NIEHS)
Amyotrophic Lateral Sclerosis, Neurodegenerative Disease
Amyotrophic Lateral Sclerosis (ALS) Tissue Donation Program
Despite significant progress in the identification of mechanisms involved in motor neuron degeneration in Amyotrophic Lateral Sclerosis (ALS) and other motor system diseases, the actual pathogenesis and cause of these diseases…
- Conditions
- Amyotrophic Lateral Sclerosis, Neurodegenerative Disease, Motor Neuron Disease
- Trial name
- NCT00716131
- Where
- United States
- Volunteers
- 205 people, healthy volunteers welcome
- Sponsor
- Drexel University College of Medicine